In a joint notification, the National Medical Products Administration (NMPA), Ministry of Public Security, and National Health Commission (NHC) of China announced adjustments to the management categories of certain psychotropic drugs. Effective July 1, 2024, dextromethorphan, diphenoxylate, nalfurafine, and lorcaserin will be placed under Category II control. Concurrently, the active pharmaceutical ingredients (APIs) and injection forms of midazolam will be upgraded to Category I from Category II, while its single-agent preparations will remain classified under Category II.
This marks the third revision to the psychotropic drug list in 2023, following adjustments in April and September. The Category II list now comprises 92 drug varieties. These regulatory changes aim to enhance the control and management of psychotropic substances to ensure public health and safety.- Flcube.com
